Status:
NOT_YET_RECRUITING
Application-Assisted Weight Management in Endometrial Cancer Fertility Preservation
Lead Sponsor:
Peking University People's Hospital
Conditions:
Endometrial Cancer
Mobile Applications
Eligibility:
FEMALE
18-60 years
Phase:
NA
Brief Summary
This study is a single-center, prospective, randomized controlled trial targeting endometrial cancer (EC) patients undergoing fertility-sparing treatment at Peking University People's Hospital from Ma...
Detailed Description
Endometrial cancer is one of the most common malignancies of the female reproductive tract, with obesity being a closely associated factor in its development and progression. According to the American...
Eligibility Criteria
Inclusion
- BMI ≥ 25 kg/m²
- Histologically confirmed endometrial carcinoma via diagnostic curettage, hysteroscopic endometrial biopsy, or needle biopsy
- Clinical FIGO 2009 stage IA disease: No evidence of extrauterine metastasis or myometrial invasion on imaging (MRI/CT)
- ECOG \< 2
- Active desire to preserve fertility
- Fertility-preserving treatment
- Willingness to participate and signed informed consent
Exclusion
- High-grade or p53-mutated (p53mut) endometrial cancer
- Currently using weight-loss medications
- Pregnant or breastfeeding
- Presence of communication barriers that prevent understanding and participation in the informed consent process
- Participation in other weight-loss programs
- Inability to safely engage in unsupervised physical activities
- Undergoing anticoagulant therapy that may affect body composition, weight, or energy expenditure
- Severe comorbidities: urinary system stones, history of renal failure or severe renal insufficiency, familial dyslipidemia, severe liver disease, chronic metabolic acidosis, history of pancreatitis, severe diabetes, active gallbladder disease, fat malabsorption, severe cardiovascular and cerebrovascular diseases
- Presence of unstable medical conditions: uncontrolled hypertension, diabetes, unstable angina, transient ischemic attack, other cancers currently under treatment, Crohn's disease
Key Trial Info
Start Date :
March 31 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 31 2027
Estimated Enrollment :
106 Patients enrolled
Trial Details
Trial ID
NCT06901778
Start Date
March 31 2025
End Date
March 31 2027
Last Update
April 3 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University People's Hospital
Beijing, China, 100044